Global Lung Cancer Drugs Market Report 2024

Lung Cancer Drugs Global Market Report 2024 – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)), By End User (Hospitals, Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

Lung Cancer Drugs Global Market Report 2024

Starting Price : $5000.00 | Pages : 175 | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Lung Cancer Drugs Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Lung Cancer Drugs Market Definition

Lung cancer drugs refer to anti-angiogenic drugs that are used to treat lung cancer. Lung cancer is a type of cancer that decreases the ability of the lungs to supply oxygen to the bloodstream because of the uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. Based on the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

The main types of diseases in lung cancer drugs are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is a type of lung cancer that grows quickly in the lungs' tissues. Small cell lung cancer has often expanded (metastasized) outside of the lungs by the time a person receives a diagnosis. This malignancy is also more likely to recur after therapy than other types of lung cancer. The different types of drugs include Gemzar, paraplatin, Taxotere, navelbine, avastin, Tarceva, Iressa, and others and are used in various sectors such as hospitals, clinics, and others.

Lung Cancer Drugs Market Segmentation

The lung cancer drugs market covered in this report is segmented –

1) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs

2) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)

3) By End User: Hospitals, Clinics, Other End-Users

Global Lung Cancer Drugs Market Size 2023 to 2028: Graph

Lung Cancer Drugs Market Size 2024 And Growth Rate

The lung cancer drugs market size has grown rapidly in recent years. It will grow from $42.3 billion in 2023 to $47.72 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to epidemiology and demographics, regulatory approvals, healthcare infrastructure, patient awareness and education.

Lung Cancer Drugs Market Growth Forecast

The lung cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $74.81 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to health insurance and reimbursement policies, healthcare infrastructure and access, emerging markets. Major trends in the forecast period include advancements in targeted therapies, immunotherapy, genomic profiling, clinical trials and research,.

Lung Cancer Drugs Market Driver: Lung Cancer Prevalence Driving The Lung Cancer Drugs Market

The rising prevalence rate of lung cancer is a major driver for the lung cancer drugs market. This is mainly because an increase in the prevalence and incidence rate of lung cancer cases propels the need for drugs that enable efficient and fast treatment of the disease. It also drives the industry to maintain a strong pipeline of drugs. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, about 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and about 127,070 deaths from lung cancer (67,160 in men and 59,910 in women) were estimated in 2023. Therefore, the rising prevalence rate of lung cancer is driving the growth of the lung cancer drugs market.

Lung Cancer Drugs Market Driver: Growing Prevalence Of Smoking Fuels Lung Cancer Drugs Market

The increasing prevalence of smoking is expected to propel the growth of the lung cancer drugs market going forward. Smoking is the act of inhaling and exhaling the fumes of burning plant material, most commonly associated with tobacco as smoked in a cigarette, cigar, or pipe. Smoking is the leading cause of lung cancer, and it is estimated that cigarette smoking explains almost 90% of lung cancer risk in men and 70 to 80% in women. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based public health agency, nearly 12 out of every 100 American citizens who were 18 years of age or older (11.5%) were current smokers in 2021. This indicates that there are currently an estimated 28.3 million adult smokers in the USA. More than 16 million Americans are affected by a condition brought on by smoking. Therefore, the increasing prevalence of smoking is driving the growth of the lung cancer drugs market.

Global Lung Cancer Drugs Market Major Players

Major companies operating in the lung cancer drugs market include Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, Shanghai Jinhe Bio-Technology Co. Ltd., Nlyte Software, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Biogen Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Jazz Pharmaceuticals plc, Karyopharm Therapeutics Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC

Global Lung Cancer Drugs Market Restraint: Growth Of Biologics And Targeted Therapies Hampers Lung Cancer Drugs Market

The increasing use of biologics and targeted therapies is a major restraint for the lung cancer drugs market. This is because chemical lung cancer drugs come with myriads of side effects and have a toxic effect on the body. Chemical drugs lack cell specificity, i.e., they destroy even the normal body cells along with cancer-infected cells. While biologic drugs are highly targeted and work on cancer-infected cells only. Biologic drugs are also very efficient with no side effects. Clinical studies have also found that the probability of success of biological drugs is much higher than that of conventional chemical drugs. For example, Cetuximab, Gefitinib, and Afatinib are lung cancer biologic drugs that specifically target only the muted form of tumours and do not destroy the normal body cells.

Global Lung Cancer Drugs Market Trend: Introducing Targeted Drug Therapy In Combination With Other Therapies For Lung Cancer Treatment

Targeted drug therapy in combination with other therapies is an emerging trend in the lung cancer drugs market. It involves the use of immunotherapy drugs combined with other therapies such as chemotherapy that help in early diagnosis, prevention, and treatment of the disease. In this regard, drug manufacturers are developing targeted drug therapies for better diagnosis and treatment of lung cancer. For example, Merck and Co. developed pembrolizumab, which is a drug that helps the immune system to detect and fight cancer cells when used in addition to chemotherapy. This combination therapy showed an improvement in lung cancer status in patients. The drug is a major product of Merck and Co. and is sold under the brand name Keytruda.

Global Lung Cancer Drugs Market Trend: Increasing Focus On New Drug Approvals To Gain A Competitive Edge In The Lung Cancer Drugs Market

Major companies operating in the lung cancer drugs market are focused on introducing new drugs and getting them approved by federal agencies to gain a competitive edge in the market. New drug approval is a process through which a pharmaceutical manufacturer or its agent requests permission from a regulatory agency, such as the US Food and Drug Administration (FDA), for final use and to market a new drug for one or more specified indications. For instance, in November 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, announced the US Food and Drug Administration's (US-based federal agency) approval of PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC). Patients must either have locally or metastatically advanced malignancies that are not amenable to definitive chemoradiation or surgical excision. This combination may be used to treat patients regardless of histology or PD-L1 expression.

Lung Cancer Drugs Market Merger And Acquisition: FDA Regulations In CFR Title 21 Part 312 Subpart E, Guidelines For Lung Cancer Drugs

The FDA's guidelines for lung cancer drugs are mentioned within the Code for Federal Regulations (CFR) title number 21 under part 312, which contains sub-parts from 'A' to 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as lung cancer. The subpart 'E' also includes guidelines for monitoring and evaluation of clinical trials of lung cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All drug manufacturers are required to abide by these regulations by the FDA. Hence, regulations such as these would also keep a check on manufacturers of lung cancer drugs.

Regional Analysis For The Global Lung Cancer Drugs Market

North America was the largest region in the lung cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The lung cancer drugs market consists of sales of bevacizumab, atezolizumab, and ramucirumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The lung cancer drugs market research report is one of a series of new reports from The Business Research Company that provides lung cancer drugs market statistics, including lung cancer drugs industry, global lung cancer drugs market size, regional shares, competitors with a lung cancer drugs market share, detailed lung cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer drugs industry. This lung cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lung Cancer Drugs Market Report Forecast And Analysis
Report AttributeDetails
Market Size Value In 2024 $47.72 billion
Revenue Forecast In 2033 $74.81 billion
Growth Rate CAGR of 11.9% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs
2) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)
3) By End User: Hospitals, Clinics, Other End-Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Bristol-Myers Squibb Company; Merck & Co. Inc.; F. Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.; GlaxoSmithKline plc; Sanofi S.A.; Sun Pharmaceutical Industries Ltd.; Celgene Corporation; Mylan N.V.; Ono Pharmaceutical Co. Ltd.; Teva Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; Ziopharm Oncology Inc.; Menarini Group; AstraZeneca PLC; Shanghai Jinhe Bio-Technology Co. Ltd.; Nlyte Software; AbbVie Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Daiichi Sankyo Company Limited; Eli Lilly and Company Inc.; Johnson & Johnson; Amgen Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; Biogen Inc.; Clovis Oncology Inc.; Eisai Co. Ltd.; Exelixis Inc.; Genentech Inc.; Gilead Sciences Inc.; Incyte Corporation; Ipsen Biopharmaceuticals Inc.; Jazz Pharmaceuticals plc; Karyopharm Therapeutics Inc.; Kyowa Kirin Co. Ltd.; Loxo Oncology Inc.; MedImmune LLC
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Lung Cancer Drugs Market Characteristics

    3. Lung Cancer Drugs Market Trends And Strategies

    4. Lung Cancer Drugs Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Lung Cancer Drugs Market Size and Growth

    5.1. Global Lung Cancer Drugs Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Lung Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Lung Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Lung Cancer Drugs Market Segmentation

    6.1. Global Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Gemzar

    Paraplatin

    Taxotere

    Navelbine

    Avastin

    Tarceva

    Iressa

    Other Drugs

    6.2. Global Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Small cell lung cancer (SCLC)

    Non-small cell lung cancer (NSCLC)

    6.3. Global Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Clinics

    Other End-Users

    7. Lung Cancer Drugs Market Regional And Country Analysis

    7.1. Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Lung Cancer Drugs Market

    8.1. Asia-Pacific Lung Cancer Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Lung Cancer Drugs Market

    9.1. China Lung Cancer Drugs Market Overview

    9.2. China Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Lung Cancer Drugs Market

    10.1. India Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Lung Cancer Drugs Market

    11.1. Japan Lung Cancer Drugs Market Overview

    11.2. Japan Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Lung Cancer Drugs Market

    12.1. Australia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Lung Cancer Drugs Market

    13.1. Indonesia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Lung Cancer Drugs Market

    14.1. South Korea Lung Cancer Drugs Market Overview

    14.2. South Korea Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Lung Cancer Drugs Market

    15.1. Western Europe Lung Cancer Drugs Market Overview

    15.2. Western Europe Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Lung Cancer Drugs Market

    16.1. UK Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Lung Cancer Drugs Market

    17.1. Germany Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Lung Cancer Drugs Market

    18.5. France Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Lung Cancer Drugs Market

    19.9. Italy Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Lung Cancer Drugs Market

    20.13. Spain Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Lung Cancer Drugs Market

    21.1. Eastern Europe Lung Cancer Drugs Market Overview

    21.2. Eastern Europe Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Lung Cancer Drugs Market

    22.1. Russia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Lung Cancer Drugs Market

    23.1. North America Lung Cancer Drugs Market Overview

    23.2. North America Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Lung Cancer Drugs Market

    24.1. USA Lung Cancer Drugs Market Overview

    24.2. USA Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Lung Cancer Drugs Market

    25.1. Canada Lung Cancer Drugs Market Overview

    25.2. Canada Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Lung Cancer Drugs Market

    26.1. South America Lung Cancer Drugs Market Overview

    26.2. South America Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Lung Cancer Drugs Market

    27.1. Brazil Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Lung Cancer Drugs Market

    28.1. Middle East Lung Cancer Drugs Market Overview

    28.2. Middle East Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Lung Cancer Drugs Market

    29.1. Africa Lung Cancer Drugs Market Overview

    29.2. Africa Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Lung Cancer Drugs Market Competitive Landscape And Company Profiles

    30.1. Lung Cancer Drugs Market Competitive Landscape

    30.2. Lung Cancer Drugs Market Company Profiles

    30.2.1. Bristol-Myers Squibb Company

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Merck & Co. Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. F. Hoffmann-La Roche Ltd.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Novartis AG

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Pfizer Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Lung Cancer Drugs Market Competitive Benchmarking

    32. Global Lung Cancer Drugs Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Lung Cancer Drugs Market

    34. Lung Cancer Drugs Market Future Outlook and Potential Analysis

    34.1 Lung Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities

    34.2 Lung Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities

    34.3 Lung Cancer Drugs Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Bristol-Myers Squibb Company Financial Performance
  • Table 75: Merck & Co. Inc. Financial Performance
  • Table 76: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 77: Novartis AG Financial Performance
  • Table 78: Pfizer Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Bristol-Myers Squibb Company Financial Performance
  • Figure 75: Merck & Co. Inc. Financial Performance
  • Figure 76: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 77: Novartis AG Financial Performance
  • Figure 78: Pfizer Inc. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the lung cancer drugs market?

Lung cancer drugs refer to anti-angiogenic drugs that are used to treat lung cancer. Lung cancer is a type of cancer that decreases the ability of the lungs to supply oxygen to the bloodstream because of the uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. Based on the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). For further insights on the lung cancer drugs market, request a sample here

How will the lung cancer drugs market drivers and restraints affect the lung cancer drugs market dynamics? What forces will shape the lung cancer drugs industry going forward?

The lung cancer drugs market major growth driver - lung cancer prevalence driving the lung cancer drugs market. For further insights on the lung cancer drugs market, request a sample here

What is the forecast market size or the forecast market value of the lung cancer drugs market ?

The lung cancer drugs market size has grown rapidly in recent years. It will grow from $42.3 billion in 2023 to $47.72 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to epidemiology and demographics, regulatory approvals, healthcare infrastructure, patient awareness and education. The lung cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $74.81 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to health insurance and reimbursement policies, healthcare infrastructure and access, emerging markets. Major trends in the forecast period include advancements in targeted therapies, immunotherapy, genomic profiling, clinical trials and research, . For further insights on the lung cancer drugs market, request a sample here

How is the lung cancer drugs market segmented?

The lung cancer drugs market is segmented
1) By Drugs: Gemzar; Paraplatin; Taxotere; Navelbine; Avastin; Tarceva; Iressa; Other Drugs
2) By Disease Type: Small cell lung cancer (SCLC); Non-small cell lung cancer (NSCLC)
3) By End User: Hospitals; Clinics; Other End-UsersFor further insights on the lung cancer drugs market,
request a sample here

Which region has the largest share of the lung cancer drugs market? What are the other regions covered in the report?

North America was the largest region in the lung cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the lung cancer drugs market, request a sample here.

Who are the major players in the lung cancer drugs market?

Major companies operating in the lung cancer drugs market include Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, Shanghai Jinhe Bio-Technology Co. Ltd., Nlyte Software, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Biogen Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Jazz Pharmaceuticals plc, Karyopharm Therapeutics Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC For further insights on the lung cancer drugs market, request a sample here.

What are the key trends in the lung cancer drugs market?

Major trend in the lung cancer drugs market - introducing targeted drug therapy in combination with other therapies for lung cancer treatment. For further insights on the lung cancer drugs market, request a sample here.

What are the major opportunities in the lung cancer drugs market? What are the strategies for the lung cancer drugs market?

For detailed insights on the major opportunities and strategies in the lung cancer drugs market, request a sample here.

How does the lung cancer drugs market relate to the overall economy and other similar markets?

For detailed insights on lung cancer drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the lung cancer drugs industry?

For detailed insights on the mergers and acquisitions in the lung cancer drugs industry, request a sample here.

What are the key dynamics influencing the lung cancer drugs market growth? SWOT analysis of the lung cancer drugs market.

For detailed insights on the key dynamics influencing the lung cancer drugs market growth and SWOT analysis of the lung cancer drugs industry, request a sample here.